Lyso-GM2 ganglioside: A possible biomarker of Tay-Sachs disease and sandhoff disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Kodama, Takashi ^a   Togawa, Tadayasu ^a   Tsukimura, Takahiro ^a   Kawashima, Ikuo ^a,b   Matsuoka, Kazuhiko ^c   Kitakaze, Keisuke ^c   Tsuji, Daisuke ^c   Itoh, Kohji ^c   Ishida, Yo ichi ^a   Suzuki, Minoru ^d   Suzuki, Toshihiro ^a   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; BIOLOGICAL MARKER; GANGLIOSIDE GM2; LYSO GANGLIOSIDE GM2; UNCLASSIFIED DRUG; BETA N ACETYLHEXOSAMINIDASE; DRUG DERIVATIVE; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; LYSOGANGLIOSIDE G(M2);

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; INFANT; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID BRAIN LEVEL; LIPID DEGRADATION; MOUSE; NONHUMAN; SANDHOFF DISEASE; TAY SACHS DISEASE; WILD TYPE; ANIMAL; BLOOD; BRAIN; ENZYMOLOGY; METABOLISM;

ADULT; ANIMALS; BIOLOGICAL MARKERS; BRAIN; G(M2) ACTIVATOR PROTEIN; G(M2) GANGLIOSIDE; HEXOSAMINIDASES; HUMANS; INFANT; MICE; SANDHOFF DISEASE; TAY-SACHS DISEASE;

EID: 83755228644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029074     Document Type: Article

References (22)

1. Graval RA, Kabach MM, Proia RL, Sandhoff K, Suzuki K, et al. (2001) The GM2 gangliosidoses. In: Scriver CR, Sly WA, Beaudet AL, Valle D, editors. The Metabolic and molecular Bases of Inherited Disease, eighth ed New York McGraw-Hill pp. 3827-3876.
2. Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, et al. (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97: 327-329.
3. Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH, (2009) Miglustat in late-onset Tay-Sahs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 11: 425-433.
4. Cachón-González MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, et al. (2006) Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA 103: 10373-10378.
5. Lee JP, Jeyakumar M, Gonzalez R, Takahashi H, Lee PJ, et al. (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13: 439-447.
6. Matsuoka K, Tsuji D, Aikawa S, Matsuzawa F, Sakuraba H, et al. (2010) Introduction of an N-glycan into HEXA enhances human β-hexosaminidase cellular uptake in a model of Sandhoff disease. Mol Ther 18: 1519-1526.
7. Tsuji D, Akeboshi H, Matsuoka K, Yasuoka H, Miyasaki E, et al. (2011) Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann Neurol 69: 691-701.
8. Matsuoka K, Tamura T, Tsuji D, Dohzono Y, Kitakaze K, et al. (2011) Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis. Mol Ther 19: 1017-1024.
9. Kuroki Y, Itoh K, Nadaoka Y, Tanaka T, Sakuraba H, (1995) A novel missense mutation (C522Y) is present in the β-hexosaminidase β-subunit gene of a Japanese patient with infantile Sandhoff disease. Biochem Biophys Res Commun 212: 564-571.
10. Hara A, Uyama E, Uchino M, Shimmoto M, Utsumi K, et al. (1998) Adult Sandhoff's disease: R505Q and I207V substitutions in the HEXB gene of the first Japanese case. J Neurol Sci 155: 86-91.
11. Sakuraba H, Itoh K, Shimmoto M, Utsumi K, Kase R, et al. (1999) GM2 gangliosidosis AB variant: Clinical and biochemical studies of a Japanese patient. Neurology 52: 372-377.
12. Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, et al. (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100: 257-261.
13. Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, et al. (2010) Tissue and plasma globortiaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun 399: 716-720.
14. Kotani M, Ozawa H, Kawashima I, Ando S, Tai T, (1992) Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochim Biophys Acta 1117: 97-103.
15. Nilsson O, Svennerholm L, (1982) Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 39: 709-718.
16. Kobayashi T, Goto I, Yamanaka T, Suzuki Y, Nakano T, et al. (1988) Infantile and fetal globoid cell leukodystrophy: analysis of galactosylceramide and galactosylsphingosine. Ann Neurol 24: 517-522.
17. Sueyoshi N, Maehara T, Ito M, (2001) Apoptosis of Neuro2a cells induced by lysosphingolipids with naturally occurring stereochemical configurations. J Lipid Res 42: 1197-1202.
18. Huang JQ, Trasler JM, Igdoura S, Michand J, Hanai N, et al. (1997) Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 6: 1879-1885.
19. Neuenhofer S, Conzelmann E, Schwarzmann G, Egge H, Sandhoff K, (1986) Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. Biol Chem Hoppe-Seyler 367: 241-244.
20. Rosengren B, Månsson J-E, Svennerholm L, (1987) Composition of gangliosides and neutral glycosphingolipids of brain in classical Tay-Sachs disease: more lyso-GM2 in Sandhoff disease? J Neurochem 49: 834-840.
21. Kobayashi T, Goto I, (1991) A sensitive assay of lysogangliosides using high-performance liquid chromatography. Biochim Biophys Acta 1081: 159-166.
22. Kobayashi T, Goto I, Okada S, Orii T, Ohno K, et al. (1992) Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses. J Neurochem 59: 1452-1458.